ArticleHuman vaccines & immunotherapeutics2021

Product review on MAbs (alemtuzumab and ocrelizumab) for the treatment of multiple sclerosis.

Tereza Gabelić et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.